Cara Therapeutics, Inc.
4 Stamford Plaza 107 Elm Street, 9th floor
Stamford
Connecticut
06902
United States
Tel: 203-567-1500
Fax: 203-567-1510
Website: http://www.caratherapeutics.com/
Email: info@caratherapeutics.com
245 articles about Cara Therapeutics, Inc.
-
Why 2018 Could be Cara Therapeutics' Year
12/12/2017
Most investors would be excited if one of the stocks they owned achieved a 45% gain in less than a year. -
Top 3 Best Biotechs of 2018
11/13/2017
Noting that biotech stocks have been in "hypergrowth" mode over more than six years, George Budwell, writing for The Motley Fool, looks at three biotech stocks that he would recommend to investors. -
Cara Therapeutics Reports Third Quarter 2017 Financial Results
11/3/2017
Management to host conference call today at 4:30 p.m. ET.
-
Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017
10/27/2017
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
-
Cara Therapeutics Doses First Patient in Phase I Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
10/25/2017
Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP).
-
Cara Therapeutics Announces Successful End-of-Phase II Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
10/16/2017
Cara, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for I.V. CR845.
-
Where High-Flying Cara Therapeutics Could be in 5 Years
10/6/2017
-
Cara Therapeutics Reports Second Quarter 2017 Financial Results
8/4/2017
-
Cara Therapeutics Could Be 1 Clinical Trial Away From a $1 Billion Valuation
8/4/2017
-
Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
8/1/2017
-
Cara Therapeutics To Announce Second Quarter 2017 Financial Results On August 3, 2017
7/28/2017
-
Cara Therapeutics Announces Summary Data From Phase I Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease
7/12/2017
-
Mixed Phase II Osteoarthritis Data Sends Cara Therapeutics' Stock Plunging
6/30/2017
-
FDA Calls Cara Therapeutics' Kidney Disease Drug a Breakthrough, Stock Soars
6/26/2017
-
Cara Therapeutics Reports Continuation Of Phase III Trial Of I.V. CR845 In Postoperative Pain Following Interim Assessment
6/21/2017
-
Cara Therapeutics: A Look At The Next Catalyst—Osteoarthritis
5/16/2017
-
Cara Therapeutics Reports First Quarter 2017 Financial Results
5/5/2017
-
Cara Therapeutics To Announce First Quarter 2017 Financial Results On May 4, 2017
4/27/2017
-
Cara Therapeutics Announces Positive Data From Quantitative Phase I Trial Measuring Respiratory Safety Of I.V. CR845
4/24/2017
-
What Makes Cara Therapeutics So Intriguing?
3/17/2017